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Abstract 
 
 Currently patients with diabetes receive most of their treatments, including 
insulin, subcutaneously. Developing a method to orally deliver proteins, peptides, and 
potentially other therapeutics has the ability to increase patient compliance by making 
treatments easier to administer. Utilizing the Vitamin B12 uptake pathway is one 
proposed method of oral delivery of protein therapeutics.  
We investigated a way to synthesize a carboxylic acid derivative of Vitamin 
B12 (B12) that could increase the ease of its conjugation to proteins and peptides. The 
5’-position of the ribose tail of B12 was oxidized using excess 2-iodoxybenzoic acid 
(IBX) and 2-hydroxypyridine (HYP). The synthesis of this B12 derivative allows for 
peptides, proteins, and other molecules to be conjugated to the 5’-position of the 
ribose tail of B12 using an amide bond instead of a carbamate bond. Conjugation of a 
simple amine-containing organic molecule, benzylamine , to this B12 derivative with a 
40% yield supported the synthesis of the derivative and its potential to increase the 
yield of B12 conjugate formation.  
We also investigated a method to recombinately express C-peptide using a 
SUMO system and Escherichia coli. The ability to deliver C-peptide orally using the 
vitamin B12 uptake pathway would be an easy treatment to potentially reduce diabetic 
neuropathy, a complication present in many patients with diabetes.   
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1 Diabetes 
1.1 Diabetes 
Diabetes is a group of diseases categorized by high levels of blood glucose. 
This can be a result of defective insulin production, use, or a combination of both. 
The two main types of diabetes are type 1 and type 2. 1 
 1.1.1 Type 1 Diabetes 
The onset of type 1 diabetes is due to the destruction of pancreatic beta cells 
by the body’s immune system. Because these cells are the body’s only source of 
insulin production, people with type 1 diabetes must receive insulin via an outside 
source, usually an injection or a pump. Type 1 diabetes usually develops during 
childhood or young adulthood and accounts for about 5% of all diagnosed cases of 
diabetes. 1 
 1.1.2 Type 2 Diabetes 
Type 2 diabetes usually begins when the body’s cells cannot use insulin 
properly. The demand for insulin in the body then rises, which eventually causes the 
pancreas to lose its ability to produce it. Aging, obesity, and family history are all 
associated with the onset of type 2 diabetes. 1 
1.2 Diabetes in the Unite States 
The Center for Disease Control and Prevention (CDC) reports diabetes as the 
seventh most common cause of death. It affects 25.8 million people or 8.3% of the 
population in the United States. Diabetes is also the primary cause of kidney failure 
and is a major contributor to stroke and heart disease. The CDC estimates that in 2010 
2 
 
 
in the United States about 1.9 million people over the age of 20 were newly 
diagnosed with diabetes. 1 
1.3 Current Treatments 
Diet, insulin, and oral medication are the main forms of treatment used to 
regulate blood glucose levels in people with diabetes. People with type 1 diabetes 
must have insulin to sustain life. However, many people with type 2 diabetes are able 
to manage their disease by just eating healthy, exercising, and losing weight in 
combination with oral medication. 12% of adults diagnosed with diabetes take insulin 
only, 14% take insulin and oral medication, 58% take only oral medication, 16% do 
not take either one. Self-management and education are also key aspects of the 
treatment of diabetes.1 
2 Vitamin B12 
2.1 Structure 
B12, a water-soluble organometallic compound, is the largest and most 
complex of all of the vitamins. 2 B12 consists of a corrin ring with the metal cobalt(III) 
at its center. 3 Cobalt has 6 coordination sites, 4 being occupied by nitrogens in the 
corrin ring. The fifth site is occupied by a ligand on the ! side. In the active forms of 
B12 in the human body, the ! ligand is a methyl group or a 5-deoxyadenosyl group 
and the compounds are called methylcobalamin and 5-deoxyadenosylcobalamin, 
respectively. In the form of B12 usually present in dietary supplements, the ! ligand is 
a cyanide group and the compound is called cyanocobalamin. In the body, 
cyanocobalamin is converted to its active forms.4 The 6th coordination site is occupied 
by 5,6-dimethylbenzimidazole, which is linked to a 5 carbon sugar. This 5 carbon 
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sugar is linked to a phosphate group that is attached to an amide group in the corrin 
ring. 3 This structure can be seen in Figure 1 below.  
 
Figure 1 Structure of Vitamin B12 
 
2.2 B12 Uptake Pathway 
B12 is an essential vitamin that cannot be synthesized by the human body. The 
average adult diet consists of an intake of 1-5 µg of B12 a day. Once ingested, 
proteases and the acidic environment of the gastrointestinal tract begin to break B12’s 
peptide bonds in order to extract it from food. 
 B12’s uptake pathway (Figure 2) begins with the binding of B12 to salivary 
haptcorrin (HC). The acidic conditions (pH<3) cause HC to have a high affinity for 
B12. HC is then able to protect B12 from acid hydrolysis, which would normally occur 
in an environment with such a low pH. Then the HC and B12 complex moves from the 
stomach into the first section of the small intestine or the duodenum. The pH in the 
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duodenum is higher than that of the stomach (>5.5), decreasing HC’s affinity for B12. 
Enzymes from the pancreas also begin to digest HC, which frees the B12 to then bind 
to intrinsic factor (IF). IF, a second transport protein, is produced in the gastric 
mucosa and the pancreas. The IF and B12 complex binds to its receptor, cubilin, to be 
transported across the intestinal enterocyte. B12 then appears in the blood bound to 
transcobalamin II (TC II). The cells take up this complex of TC II and B12. B12 is 
finally freed from this complex after a lysozyme degrades TC II.5 
 
 
 
 
 
 
 
55!
!
and the intestinal IF dependent cubam complex.  HC is important for the protection of B12 in the 
mouth/stomach and facilitates the transport of B12 to the intestines, where the second transport 
protein IF transports the B12 across the intestinal wall with the aid of the cubam complex (see 
section 1.4.7)." 
 
 
F igure 18.  A basic representation of the B12 dietary uptake pathway.  
 
Previously, Petrus et al. reported on the development and characterization of an orally 
active B12-insulin conjugate with hypoglycemic properties in the streptozotocin (STZ)-induced 
diabetic rat model.#$  The oral administration of the B12-insulin conjugate resulted in a 4.7 fold 
greater decrease in blood glucose levels compared to orally administrated insulin in the STZ rat 
model.  It was determined that the B12- ing ability was a result of the use 
of the B12 uptake pathway.  This determination was based on experimentation with co-
Figure 2: Representation of B12 uptake pathway 
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3 The Use of Vitamin B12 in Oral Delivery 
3.1 Background 
Many therapeutic peptides and proteins are currently given intravenously. 
Although oral administration of these therapeutics would be an ideal alternative route 
of delivery in order to increase patience compliance and comfort, two main barriers 
stand in the way. First of all, the acidic environment of the gastrointestinal tract 
would degrade any protein or peptide, leaving it in an inactive form. Second of all, 
the body does not have a method or pathway to absorb these peptides and proteins 
from the gastrointestinal tract into the bloodstream. 5 If these two problems could be 
solved, then the oral delivery of peptides and proteins would be a feasible method to 
deliver medications, improving the lives of many. For example, the ability to deliver 
insulin orally would increase the ease at which it can be administered to those with 
diabetes. This could significantly increase patient compliance, lowering the 
complications and deaths each year caused by diabetes. 
The utilization of the B12 uptake pathway described in section 2.2 has been a 
method of oral delivery of peptides and protein receiving increasing attention over the 
past decade. If proteins and peptides can be conjugated to B12, B12’s mechanism for 
delivery within the body naturally has ways to protect the proteins and peptides from 
the acidic environment in the gastrointestinal tract and allow them to be absorbed into 
the bloodstream. 5 
3.2 Conjugation Sites 
When coupling B12 and a peptide, protein, or any other molecule, it is 
important that both entities maintain their biological function in the body. The 
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functional sites of the peptide, protein, or molecule must still be intact in order to 
work properly once it reaches the bloodstream. In addition, the sites on B12 
recognized by the proteins in its uptake pathway must still be recognizable. There are 
three major sites on B12 that are believed to not interfere with its recognition in its 
uptake pathway. 5 
 1) The e peripheral propionamide on the corrin ring 
 2) The ribose 5’-hydroxy group  
 3) The phosphate unit on the " tail  
These sites are highlighted in figure 3 below. 
 
 
Figure 3: Potential sites of conjugation on B12 
 
1 
2 
3 
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4 C-peptide 
4.1 Background 
C-peptide is a protein that contains 31 amino acids. It is part of the proinsulin 
(Figure 4) produced from pre-proinsulin translated off the ribosome and is 
synthesized by the beta cells of the pancreas. After C-peptide is cleaved from 
proinsulin, Insulin is released into the body in its active form, along with an 
equimolar amount of C-peptide. For a long time, C-peptide was thought to be 
biologically inert and therefore people with diabetes only received injections of 
supplemental insulin, not C-peptide. However, recent studies have suggested that C-
peptide may serve a regulatory role in the body by contributing to vascular 
homeostasis in various tissues. Upon the administration of C-peptide, a number of 
cellular responses occur in insulin dependent patients with diabetes, such as a “rise in 
blood flow to the kidneys, muscle, skin, and nerves in the diabetic state.” 6 For 
patients with diabetes, the lack of C-peptide in combination with high blood glucose 
levels reduces microvascular circulation, which can eventually lead to complications 
like neuropathy. 5,6 
  
 
6!
!
cleave between residue 32 and 33 at the C-peptide/B-chain junction and residue 65 and 66 at the 
C-peptide/A-chain.""  The removal of extra basic residues at the C-terminal end of the B-chain 
and C-terminal nd of C-peptide occurs by CPE. 
F igure 3.  The post-translational modifications of preproinsulin, which results in active 
monomeric insulin and C-peptide. 
 
 Pancreatic  cells secrete insulin in a tightly regulated fashion to ensure glucose 
homeostasis."#  The mechanism for insulin secretion is a complex process involving the 
integration of intracellular and extracellular components and is still not completely understood 
(see Figure 4).  Nutrients, hormones, and neurotransmitters have all been shown to directly 
Figure 4: Representation of Human Proinsulin 
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5 Site-Selective Oxidation of Vitamin B12 
5.1 Background 
As mentioned prior, there are several potential sites for conjugation to B12, 
however conjugation has most successfully occurred at (1) the 5’-hydroxyl group of 
the ribose and (2) the e propionamide of the peripheral corrin ring (Figure 5). 
Fortunately, neither site interferes with the proteins of the B12 uptake pathway. 
Although the carboxylic acid derivative of the e propionamide group has been made, 
it is low yielding and difficult to purify. This is partially attributed to the 
simultaneous synthesis of the b-, d-, and e- acid derivatives. The 5’-hydroxyl group of 
the ribose of B12 is a versatile site that could potentially be used for the synthesis of a 
variety of B12 conjugates. However, limited chemistry with the hydroxyl group can be 
performed and the conjugates synthesized using this site are done through a 
carbamate or ester bond shown in Figure 6. This presents stability issues and the 
potential for degradation. The selective oxidation of the 5’-hydroxyl group of B12 to a 
carboxylic acid was done using 2-iodoxybenzoic acid (IBX). This has the potential to 
increase the chemistry available at B12’s 5’-position and the ability to form conjugates 
through a more stable amide bond (Figure 6). 8,9    
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Figure 5: Sites available for conjugation to B12. This figure also shows potential B12 
derivatives to Carboxylic Acids. The numbering is used for NMR.  
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Figure 6: Carbamate, Ester, and Amide Bond examples 
 
5.1.1 2-Iodobenzoic Acid (IBX) 
Hypervalent iodine reagents, like IBX, are used in many oxidation reactions. 
Most iodinanes are advantageous for oxidations due to their availability, ability to 
regenerate, mild reaction conditions, and stability in the presence of oxygen and 
moisture. In literature it was found that the combination of IBX and N-
Hydroxysuccinimide (NHS) produces activated esters and carboxylic acids from 
alcohols. NHS is used as an activating agent that helps to bring the oxidation state 
from the alcohol to the aldehyde all the way to the desired to the carboxylic acid. 
Although the use of IBX for an oxidation reaction is seen in literature, this is the first 
 
Carbamate Bond 
 
Ester Bond 
 
Amide Bond 
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time it has been utilized for a molecule like B12, expanding its array of possible 
reactions. 10  
5.2 Synthesis of 5’-Carboxylic Acid of B12 Ribose Tail 
Beginning with the method developed by Giannis et al., a reaction to 
synthesize the B12 carboxylic acid derivative was created. This reaction uses an O-
nucleophile, NHS, in conjunction with IBX to oxidize primary alcohols. The initial 
use of NHS with IBX for the oxidation of the 5’-hydroxyl group on the ribose of B12, 
resulted in a mixture of products from which the carboxylic acid could not be 
isolated. This mixture of products was likely due to the simultaneous formation of the 
activated ester along with the carboxylic acid. The activated ester has been reported to 
be the dominant product of this reaction.10  2-hydroxypyridine (HYP) was then used 
in place of the NHS as the O-nucleophile, which provide better results. The proposed 
reaction mechanism can be seen in Figure 7. 
12 
 
 
 
Figure 7: Proposed mechanism of the synthesis of B12CA using IBX and HYP 
 
B12 (10.0mg, 0.007 mmol), IBX (5.37 mg, 0.019 mmol), and HYP (3.51 mg, 
0.037 mmol) were dissolved in 1 mL of dimethyl sulfoxide (DMSO). Using these 
reactants, a series of various experiments were conducted in order to optimize this 
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reaction. Conditions such as the co-oxidant, temperature, and the time were varied. 
These results can be seen in Figure 8 below.  
 
Co-oxidant Temperature (°C) Time (hours) % Yield 
None 50 2 17 
HYP 50 2 23 
HYP 50 3 26 
HYP 50 4 28 
HYP 50 5 22 
HYP 60 2 30 
 
 
After many reactions, the optimal conditions were determined to be 5 
equivalents of HYP for every 2.6 equivalents of IBX in DMSO at 60°C. As shown in 
Figure 8, it resulted in a 30% yield of the 5’-carboxylic acid derivative of B12 
(B12CA) over a two hour time period. It was also noted that using a temperature 
above 60°C or a time deviating from two hours for this reaction increased the amount 
of byproducts and/or degradation of B12, making the B12CA difficult to purify and 
reducing its yield. In addition, using an IBX:HYP ratio that differed from 2.6:5 
equivalents resulted in an increase of byproducts, and therefore a decrease in percent 
yield of the B12CA. When comparing the synthesis of the B12CA to that of the e-
 
Figure 8: Reaction Optimization 
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carboxylic acid derivative (Figure 5), the purification process was much easier and 
the yield was almost three times as high.8, 11  
  In order to prepare the reaction product for purification, it was precipitated out 
of the DMSO into diethyl ether. The ether was decanted and the solid product was 
allowed to air dry. The solid product was then re-dissolved in water.  
 The purification process was done using high-performance liquid 
chromatography (HPLC) and an Agilent SAX analytical column (5 µm, 9.4 X 250 
mm), which utilized ion exchange chromatography. Solvent A was ultra purified 
water and solvent B was a 50:50 mixture by volume of Acetonitrile (MeCN) and 
phosphate buffer pH 2. Note that an increase in pH for solvent B resulted in a 
decrease in the amount of purified B12CA.  
With a flow rate of 1 mL/minute, 100% of solvent A was allowed to flow 
through the HPLC and column for 5 minutes. This was followed by a gradient from 
100% solvent A, 0% solvent B to 65% solvent A, 35% solvent B over 5 minutes. The 
HPLC profile can be seen in Figure 9 below. 8,11 
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Figure 9: HPLC spectra of B12CA purification, monitored at 360 nm. The retention 
time of the unreacted B12 and aldehyde was about 5 minutes and the B12CA was about 
12 minutes.  
 
 
The peak at a retention time of 5 minutes was identified as a mixture of 
unreacted B12 and the ribose 5’-aldehyde B12 derivative. The peak with a retention 
time of about 12 minutes was identified as B12CA, the desired product. The peak at 
12 minutes, which was red in color, was collected and neutralized. It was mixed with 
amberlite XAD4 resin and rocked overnight in order to remove any salt. The 
amberlite resin turned red, suggesting the binding of the B12CA. The resin was 
collected and washed with water to remove any excess salt. The resin was placed in 
Methanol (MeOH), which would release the B12CA. The MeOH solution containing 
the B12CA was collected and lyophilized to get rid of the MeOH and leave a red 
powder product. 8,11 
Time (minutes) 
A
bs
or
ba
nc
e 
B12CA ! 
B12 and B12 5’-aldehyde 
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5.3 Identification of B12CA 
Various methods were chosen to support the identification of the synthesized 
product as B12CA.  
5.3.1 Matrix Assisted Laser Desorption Ionization (MALDI) 
Matrix Assisted Laser Desorption Ionization Time-of-Flight (MALDI-ToF) 
mass spectrometry was done using a Bruker Autoflex II Smartbeam machine with 
laser intensity from 50-73%. A small sample of the purified product (B12CA) was 
taken and mixed with a matrix containing "-cyano-4-hydroxycinnamic acid (CHCA) 
in a 1:1 volume ratio of water and acetonitrile with 0.1% trifluoroacetic acid (TFA). 
Angiotensin I was also added for use as an internal control, which has a mass to 
charge ration (m/z) of 1296. The mass to charge ratio expected for a product 
containing B12CA is m/z=1343.5 [M-CN]+. This peak was present in the MALDI 
profile as shown in Figure 10, supporting the synthesis of B12CA.  
 
17 
 
 
 
Figure 10: MALDI-ToF of the reaction product. At m/z=1296.7 the expected 
angiotensin peaks can be seen and at m/z=1343.5 the expected B12CA peaks can be 
seen.  
 
MADLI-ToF was also performed for the HPLC fractions with a retention time 
of 5 minutes, which was speculated to be the unreacted B12 and 5’-aldehyde B12 
derivative. The large group of peaks in Figure 11 is a mixture of the expected 
MALDI-ToF pattern for B12 with m/z=1329.5 and the 5’-aldehyde B12 derivative with 
m/z= 1327.5. This supports the identification of the HPLC fractions with a retention 
time of 5 minutes.8,11 
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F igure 44.  MALDI-ToF MS spectrum of HPLC peak at Tr =14 mins indicati g 4 ([M-
CN]+ 1343.5 m/z) with angiotensin as an internal reference.  
 
Electronic absorption spectroscopy (EAS) was used to determine the oxidation 
state of the metal center, nature of the axial ligands bond to the metal center and yield of 
C
361 = 27500 M-1 cm-1) (see Figure 45). 
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Figure 11: MALDI-ToF of the HPLC peak at 5 seconds. The expected angiotensin 
peaks can be seen at m/z=1296.7, B12 at m/z=1329.5, and the 5’-aldehyde B12 
derivative at m/z= 1327.5. 
 
5.3.2 Electron Absorption Spectroscopy (EAS)  
Electron Absorption Spectroscopy (EAS) was used to determine the yield of 
the B12CA product. The spectrum is shown in Figure 12 below. The yield was 
calculated using Beer-Lambert law in which A= #lc, where A is the absorption, # is 
!"#
#
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the extinction coefficient, l is the path length, and c is the concentration. For B12CA 
the extinction coefficient used was #=27500 M-1cm-1.  
 
Figure 12: Electronic Absorption Spectrum of B12CA taken in 35% B from HPLC run 
 
5.3.3 1D and 2D Nuclear Magnetic Resonance Analysis of B12CA 
Using 1H Nuclear Magnetic Resonance (NMR) (Figure 13) and 1H-13C 
heteronuclear (HSQC) (Figure 14), confirmation of the formation of B12CA was 
further supported. Looking at the 1H NMR for the B12CA and comparing it to that of 
a standard B12 Cyanocobalamin 1H NMR (Figure 15), it can be seen that 2 protons 
were lost in the formation of B12CA. These protons are located at $H=3.75 and 3.92 in 
the B12 Cyanocobalamin 1H NMR. In order to determine which two protons were lost, 
a comparison of HSQC of standard B12 Cyanocobalamin and B12CA was done 
(Figure 16). The signal that disappears at $H=63.3 in the HSQC of B12CA indicated 
that the protons lost in going from B12 to B12CA were attached to the R5 carbon. 8, 11 
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F igure 45.  Absorbance spectrum of 4 in 35 % HPLC mobile phase B. 
  4.2.2 1D and 2D N M R analysis of 4 
The structure of 4 was determined by assignments obtained from 1H NMR (see 
Figure 46) and 1H-13C heteronuclear (HSQC and HMBC) correlations (see Figures 47 
and 48).  The 1H NMR spectra of 4 H = 3.75 and 3.92), 
when compared to the spectrum of B12 (CNCbl) (see Figure 49).  A comparison of the 
HSQC of B12 and 4 indicates the protons lost in 4 were originally attached to the R5 
C = 63.3) (see Figure 50).  HMBC was then chosen to further establish the 
addition of a carbonyl at the R5 position (see Figure 48), however it was established that 
the R5 carbon shows no connectivity to any of the ribose protons and so was assigned by 
HSQC."# 
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Figure 13: 500 MHz 1H NMR of B12CA 
 
 
Figure 14: 500 MHz 1H-13C HSQC NMR of B12CA 
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F igure 46.  500 MHz 1H NMR spectrum of 4. 
. 
F igure 47.  500 MHz 1H-13C HSQC NMR spectrum of 4. 
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F igure 46.  500 MHz 1H NMR spectrum of 4. 
. 
F igure 47.  500 MHz 1H-13C HSQC NMR spectrum of 4. 
21 
 
 
 
Figure 15: 500 MHz 1H NMR of B12 
 
 
Figure 16: Zoomed in portion of 500 MHz 1H-13C HSQC NMR of B12 (left) and 
B12CA (right). Note the loss of the protons at $H=3.75 and 3.92 when the carbon at R5 
($H=63.3) is oxidized.  
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F igure 49.  500 MHz 1H NMR spectrum of B12 (CNCbl). 
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5.4 Conjugation of Benzylamine to B12CA 
Benzylamine was chosen to conjugate to the B12CA. Benzylamine is a simple 
amine-containing organic molecule and was chosen because of its easily identifiable 
diagnostic peaks present in an NMR profile. This would help to characterize the R5 
carbon even further. In addition, it would help to confirm the synthesis of the B12CA 
by showing that a simple amine could be conjugated to the carboxylic acid at the 5’ 
position on the ribose of B12. 
5.4.1 Synthesis of Conjugate 
The B12CA and benzylamine were dissolved in dimethylformamide (DMF) 
containing 1% water, along with 10 molar equivalents of ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) and 20 molar equivalents 1-
hydroxybenzotriazole (HOBt). This was left at room temperature for 1 hour to allow 
the reaction to occur. During this time, the B12CA-benzylamine (B12CABA) 
conjugate was synthesized with a 40% yield. The reaction is shown in figure 17 
below. 
 
Figure 17: The reaction of B12CA with benzylamine (1) to form B12CABA 
using EDC and HOBt in DMF for 1 hour at room temperature. 
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F igure 51. Synthesis of 5.  
5 was purified using the same purification method as established for the 
carboxylic acid (see Figure 52) and characterized by MALDI mass spectrometry (see 
Figure 53) as well as 1D (see Figure 54) and 2D NMR (see Figure 55 and 56). 
 
F igure 52. Purification of the conjugate was established by RP-HPLC using an SAX 
column with a gradient from 100% water to 35% MeCN: phosphate buffer pH 2. 
1 
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5.4.2 Purification of Conjugate 
Using the same HPLC method established to purify the B12CA from the 
original reaction, the B12CABA was purified. This involved ion exchange with an 
SAX column, a flow rate of 1 mL/minute, and 100% of solvent A flowing through the 
HPLC and column for 5 minutes. This was followed by a gradient from 100% solvent 
A, 0% solvent B to 65% solvent A, 35% solvent B over 5 minutes. Solvent A was 
ultra purified water and solvent B was a 50:50 mixture by volume of Acetonitrile 
(MeCN) and phosphate buffer pH 2. The profile obtained is shown in Figure 18. 
 
Figure 18: HPLC profile of B12CABA 
5.4.3 Identification of B12CABA 
The B12CABA was plated for MALDI, again using CHCA in a 1:1 volume 
ratio of water and acetonitrile with 0.1% TFA. Angiotensin I was used for an internal 
control. The MALDI-ToF profile of B12CABA showed a mass to charge ratio of 
m/z=1432.5, which is what was expected if the conjugations was successful (Figure 
19).  A close up of the benzylamine MALDI peaks can be seen in Figure 20. 
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F igure 51. Synthesis of 5.  
5 was purified using the same purification method as established for he
carboxylic acid (see Figure 52) and characterized by MALDI mass spectrometry (see 
Figure 53) as well as 1D (see Figure 54) and 2D NMR (see Figure 55 and 56). 
 
F igure 52. Purification of the conjugate was established by RP-HPLC using an SAX 
column with a gradient from 100% water to 35% MeCN: phosphate buffer pH 2. 
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Figure 19: MALDI-TOF of the B12CABA. The expected angiotensin peaks can be 
seen at m/z=1296.7 and B12CABA at m/z=1432.6 
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Figure 20: Up close of figure 0 of the B12CABA m/z=1432.6.  
 
Next, 1H NMR (Figure 21) of the B12CABA was done to further support the 
synthesis of the B12CABA. Looking at the 1H NMR for the B12CABA and comparing 
it to that of B12CA, the appearance of the set of peaks just below $H =7.5 is diagnostic 
of the addition of the benzylamine.  
26 
 
 
 
Figure 21: 500 MHz 1H NMR of B12CABA 
  
1H-13C HSQC NMR (Figure 22) and 1H-13C HMBC NMR (Figure 23) were 
also performed on the B12CABA to study the connectivity to the R5 carbon. From the 
HMBC, it can be seen that the R5 carbon ($C=173.8 ppm) of B12CA is connected to 
the two protons of CA of the benzyl amine ($H=4.42 and 4.50 ppm). The protons of 
CA also show direct connectivity to CB ($C=140.8 ppm) and CC ($C= 131.4 ppm) of 
the benzylamine. The numbering assignments of the atoms as well as the signal 
assignments of the B12CABA for HSQC and HMBC can be seen in Figure 24. 8, 11 
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Figure 22: 500 MHz 1H-13C HSQC NMR of B12CABA 
 
Figure 23: 500 MHz 1H-13C HMBC NMR of B12CABA 
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Figure 24: A: Numbering assignments of B12CABA, B: Signal assignments of the 
HSQC of B12CABA, C: Signal assignments of the HMBC of B12CABA 
 
5.5 Conclusion 
In conclusion, we have successfully made a derivative of B12 that could 
increase the ease at which B12 conjugates are made. We have not only shown that IBX 
can be used for the oxidation of B12, but this oxidation is site specific of the ribose 5’-
hydroxyl group. The B12CA is synthesized with a yield that triples the synthesis of the 
carboxylic acid derivative of the propionamide or any other reported carboxylic acid 
derivative of B12. It is also much easier to purify and quicker to make. The formation 
of a derivative of B12 that has a carboxylic acid instead of a hydroxyl group available 
for conjugation increases the chemistry that can be performed at the 5’ site. This will 
allow higher yielding and more stable conjugates to be formed in the future. This 
conjugate will be of significant use in the field of B12 conjugation chemistry. 8, 11 
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F igure 56.  500 MHz 1H-13C HMBC of 5. 
 
F igure 57.  Analysis of 5 by 2D het ronuclear N R spectroscopy. A . The atom 
numbering scheme for the benzylamine attached to the R5 of B12 by an amide bond. B . 
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NOTE: Section 5 information and images were all reproduced with permission and 
acknowledgement to citations 8 and 11 in references.   
6 Expression of C-peptide 
6.1 Introduction 
As mentioned prior, administration of C-peptide has the potential to reduce 
diabetic neuropathy, a major complication that arises in many people with diabetes. 
Currently a subcutaneous administration of C-peptide is being studied for use in 
patients with diabetes7, however the ability to deliver C-peptide orally has the 
potential to be more convenient for patients with diabetes and therefore increase 
patient compliance. Utilization of the B12 uptake pathway by conjugating C-peptide to 
the 5’-carboxylic acid derivate of B12 we have created (B12CA), could allow the oral 
delivery of C-peptide.  
6.2 Recombinant Expression of C-peptide 
6.2.1 Sumo System 
In order to create a conjugate of B12 and C-peptide, the first step was to 
establish a method of expressing recombinant C-peptide. The system chosen to do so 
with was a Small Ubiquitin-like Modifier (SUMO) system, made by the Lucigen 
Corporation. The SUMO protein contains 100 amino acids and aids in the expression 
of difficult target proteins by enhancing the protein’s solubility and expression. The 
SUMO system contains a 6xHis-Sumo tag, which is used for purification. The SUMO 
system also does not require purification of the PCR product or restriction enzymes 
prior to ligation.  
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6.2.2 Amplification of C-peptide 
The target protein, C-peptide was amplified using Polymerase Chain Reaction 
(PCR). Three different PCR reactions were done with a 1:10, 1:5, and 1:1 volume to 
volume ratio of DNA to water. The DNA used was a pUC57 plasmid containing the 
target gene C-peptide, which was ordered. The primers were also designed (Figure 
25) based on the instructions in the Lucigen SUMO manual in order to synthesize the 
C-peptide PCR product with the correct flanking sequences needed for the ligation 
into the SUMO containing vector. 
 
Forward Primer: 5’-CGCGAACAGATTGGAGGTGCGGAAGATCTGCAAGTG-3’ 
Reverse Primer: 5’-GTGGCGCCCGCTCTATTATTGCAGAGAGCCTTCCAG-3’ 
Figure 25: Primers for C-peptide Insertion into the SUMO system 
 
The PCR mixture consisted of 10 µL of the different DNA to water ratios 
described above, 20 µL of sterile water, 5 µL of a 10 µM concentration of the forward 
primer, 5 µL of a 10 µM concentration of the reverse primer, 5 µL of thermopol 
buffer, 4 µL of dNTPs, and 1 µL of deep vent enzyme. The PCR conditions were 34 
cycles of 94°C for 1 minute, 60°C for 1 minute and 74 °C for 20 seconds.  
The 3 different PCR products were then run down a DNA agarose gel (0.5 
grams of agarose, 50 mL of 1X TBE buffer, 2.5 µL of Ethidium Bromide) for 70 
minutes at 70 Volts (Figure 26). C-peptide plus the flanking sequences added for 
ligation contains about 100 base pairs and can be seen in all 3 lanes of the varied PCR 
reactions near the 0.100 kilobase marker, supporting its synthesis.  
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Figure 26: Agarose Gel of PCR product. C-peptide plus the flanking sequences added 
contain about 100 base pairs and can be seen at around the 0.100 kilobase marker in 
all 3 lanes.  
  6.2.3 Ligation 
The Lucigen Corporation Sumo kit contained a linearized pETite N-His 
SUMO Kan vector, which includes the SUMO sequence. On each end of the 
linearized sequence the flanking sequences are complementary to that of the C-
Markers PCR 1:10 
PCR 
1:5 
PCR 
1:1 
Kilobases 
0.1 
0.2 
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peptide PCR product made, which helps to ligate the C-peptide and the vector. The 
ligation was done by adding 2 µL of the pETite vector linearized DNA and 3 µL of 
the PCR product to thawed chemically competent HI-Control 10G cells. Lucigen 
Corporation optimizes these cells for a high efficiency transformation. The cells were 
allowed to sit on ice for 30 minutes, then they were heat shocked by being placed in 
water at 42°C for 45 seconds. 960 µL of recovery media was added to the cells and 
then the cells were left on ice for 2 minutes. Finally the cells were placed at 37°C for 
1 hour. The cells were then plated on LB Kanamycin (Kan) Agar plates and incubated 
at 37°C overnight. Single colonies that grew on the plates were selected and grown in 
5 mL of LB and 5 µL of Kan overnight at 37°C, 250 RPM. The plasmid was then 
isolated and sent for sequencing. The sequence confirmed that a successful ligation 
had occurred between the C-peptide and the pETite N-His SUMO Kan vector. 
 6.2.4 Induction 
 Following the successful ligation, SUMO C-peptide was expressed from the 
pETite N-His SUMO Kan vector. Single colonies were selected and grown in 5 mL 
of LB and 5 µL of Kan overnight at 37°C, 250 RPM. In the morning, 0.5 mL of this 
culture was taken and placed in 50 mL LB broth with 50 µL of Kan. It was grown at 
37°C, 250 RPM until the OD600 was 0.4-0.6. The cultures were then induced with 
either 5 µL of 1 mM isopropylthiogalactoside (IPTG) or 5 µL of 0.1 mM IPTG, 
giving the final concentration of IPTG in either culture as 0.1 mM and 0.01 mM, 
respectively. Samples of each culture were taken prior to the addition of IPTG, at 1 
hour after, 4 hours, and overnight. The samples were poured into falcon tubes, 
centrifuged, and decanted. Each sample was redissolved in 20 mM tris-HCl, 150 mM 
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NaCl pH 7.2. The samples were then lysed by being sonicated on ice with 10 pulses, 
2 minutes of incubation on ice, two times. They were then centrifuged and the 
supernatant, containing the proteins, was collected. 
  6.2.5 Purification 
The supernatant following the lysis was purified using Fast Protein Liquid 
Chromatography (FPLC). A nickel resin HisTrap column was used, along with 20 
mM Hepes, 0.5 M NaCl, pH 7.2 for solvent A and 20 mM Hepes, 0.5 M NaCL, pH 
7.2 with 250 mM Imidizole for solvent B. 100% A was run through the column, 
followed by 100% B. The histag in the sumo system first bound to the column during 
the initial flow through of solvent A. It was then eluted as solvent B flowed through 
the column and imidizole displaced it. The FPLC profile is shown in Figure 27.  
 
 
Figure 27: FPLC profile of SUMO C-peptide system.  
 
Flow Through 
Eluted 
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  6.2.6 Cleavage of SUMO 
 In order to cleave the SUMO protein from C-peptide, the eluted from the 
FPLC purification was collected and boiled for 5 minutes with 1.5 µL of 
Dithiothreitol (DTT). 0.5 µL of the SUMO protease was added. The mixture was left 
at 30°C for 1 hour. The SUMO protease recognizes SUMO’s tertiary structure and 
cleaves at its terminal carboxyl group. In theory, it should leave the target protein (C-
peptide) without any extra residues. However, an SDS-Page gel was done (Figure 28) 
and showed that the C-peptide was not being cleaved from the SUMO system. If C-
peptide was cleaved from the SUMO protein, then after the digestion there should be 
two bands, one for each the SUMO and C-peptide. In the gel in Figure 28, there is 
only one band that did not change position after the digestion. SUMO is about 18 kDa 
and C-peptide is about 3 kDa. 
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Figure 28: SDS-Page gel. Lane 1: Low range protein ladder markers, Lane 2: Pre-
induction control, Lane 3: Overnight induction crude, Lane 4: FPLC flow through, 
Lane 5: FPLC eluted, Lane 6: After Dialysis, Lane 7: Digestion 
 
Different conditions were changed in order to try and get the cleavage to 
occur. This included varying the temperature, the use of DTT and urea, and the 
protease concentration and type. However, after many attempts at cleavage of the 
SUMO protein and C-peptide, it was decided that a different method of cleavage was 
necessary.  
 
kDa 
40 
25 
15 
10 
4.6 
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  6.2.7 The Addition of Factor Xa 
 Because the SUMO protease recognizes SUMO’s tertiary structure in order to 
cleave the protein, it was decided a protease was needed that recognized a definitive 
sequence and not a particular folding pattern. Factor Xa protease was chosen, which 
cleaves after Arginine in the cleavage site Isoleucine-Glutamic Acid-Glycine-
Arginine (IEGR). New primers were designed to incorporate the factor Xa site into C-
peptide (Figure 29).  
 
Forward Primer: 
5’CGCGAACAGATTGGAGGTATTGAAGGCCGCGAAGCGGAAG3’ 
Reverse Primer:  
5’ GTGGCGGCCGCTCTATTATTGCAGAGAGCCTTCCAG3’ 
Figure 29: Primers for C-peptide with Factor Xa 
 
The PCR product was amplified as in section 6.2.2 and ligated as in section 
6.2.3 into HI-control 10G cells. After many attempts, it was clear that the ligation was 
not occurring. Instead, a DNA sequence was ordered that contained SUMO, a Factor 
Xa cleavage site, and C-peptide (Figure 30). Two different restriction sites were also 
added to each end in order to digestion and ligate this DNA sequence into a vector, 
pET-15b. Based on the restriction sites available in pET-15b, Nde1 and BamH1 were 
chosen as the restriction enzymes/sites. The DNA sequence arrived in pUC57. 
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Figure 30: Ordered DNA sequence containing SUMO, Factor Xa, and C-peptide. A 
shows a representation of the parts of the sequence and B shows the actual DNA 
sequence 
 
 Once the DNA was received, both the DNA sequence and pET-15b were 
digested to prepare for ligation. 4 µL of pET-15b, 1 µL Nde1 protease, 2 µL buffer 4, 
and 11 µL of sterile water were mixed in one eppendorf tube. 4 µL of the ordered 
DNA sequence in pUC57, 1 µL Nde1 protease, 2 µL buffer 4, and 11 µL of sterile 
water were mixed in another eppendorf tube. Both were placed at 37°C for 30 
minutes. Then to the pET-15b eppendorf tube, 1 µL Calf Intestinal Phosphatase (CIP) 
and 1 µL of BamH1 were added To the DNA sequence eppendorf tube, 1 µL of sterile 
water and 1 µL of BamH1 were added. Both reactions were placed back at 37°C for 
60 minutes.  
Using an agarose gel and the E.Z.N.A kit, the digested DNA (C-peptide) and 
vector were purified and extracted. Molar ligations were performed in the following 
ratios: 1:1 2 µL C-peptide/1 µL vector, 3:1 6 µL C-peptide/1 µL vector, 5:1 10 µL C-
A:  Nde1His8SUMOFactorXaC-peptideBamH1StopCodon 
 
 
B: 
CATATGCATCACCATCACCATCACCATCACATATGCATCATCACCACC
ATCACGGGTCCCTGCAGGACTCAGAAGTCAATCAAGAAGCTAAGCCA
GAGGTCAAGCCAGAAGTCAAGCCTGAGACTCACATCAATTTAAAGGT
GTCCGATGGATCTTCAGAGATCTTCTTCAAGATCAAAAAGACCACTCC
TTTAAGAAGGCTGATGGAAGCGTTCGCTAAAAGACAGGGTAAGGAAA
TGGACTCCTTAACGTTCTTGTACGACGGTATTGAAATTCAAGCTGATC
AGACCCCTGAAGATTTGGACATGGAGGATAACGATATTATTGAGGCTC
ACCGCGAACAGATTGGAGGTATTGAAGGCCGCGAAGCGGAAGATCTG
CAGGTGGGCCAGGTGGAACTGGGCGGCGGCCCGGGCGCGGGCAGCC
TGCAGCCGCTGGCGCTGGAAGGCAGCCTGCAGGGATCCUAA 
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peptide/1 µL vector, 10:1 20 µL C-peptide/1 µL vector. To each of these, 2 µL of 
buffer, 1 µL of T4 ligase, and enough sterile water to make each reaction mixture 21 
µL were added to complete the ligation mixtures.  
3 µL of each ligation mixture was then added to BL21(DE3) cells thawed on 
ice to begin the transformation. The cells with the added ligation mixture were 
incubated on ice for 30 minutes and then heat shocked for 45 seconds at 42°C. 960 
µL of recovery media was added and the cells were allowed to sit on ice for 2 
minutes. The cells were then plated on LB Ampicillin (AMP) Agar plates and grown 
overnight at 37°C.  
All of the plates grew as expected and twelve singles colonies were selected, 
grown overnight in 5 mL LB, 5 µL AMP at 37°C, 250 rpm. The plasmid was isolated 
from two of the cultures that had grown and sent for sequencing. The sequence 
confirmed that a successful ligation had occurred between the C-peptide sequence 
and the pET-15b vector.  
The colonies with the correct sequences were selected, induced, and lysed as 
in section 6.2.4. An SDS-Page gel was ran (Figure 31) of the various time points (pre-
induction, 1 hour after, 4 hours, overnight) and IPTG concentrations (0.1 mM and 
0.01 mM). The gel did not show a band near 20-21 kDa, which is where the Sumo C-
peptide should appear. After multiple attempts, the cells did not appear to be lysing 
properly, so a more effective method of lysing the cells is currently being developed 
by increasing the length of sonication. 
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Figure 31: SDS-Page gel of SUMO, Factor Xa, and C-peptide system after induction 
and lysis. Lane 1: Precision Plus Protein Standards, Lane 2: Pre-induction control .01 
IPTG, Lane 3: 1 hour .01 IPTG, Lane 4: 4 hours .01 IPTG, Lane 5: O/N .01 IPTG, 
Lane 6: PIC 0.1 IPTG, Lane 7: 1 hour 0.1 IPTG, Lane 8: 4 hours, 0.1 IPTG, Lane 9: 
O/N 0.1 IPTG 
 
6.3 Conclusion 
Although the cleavage of C-peptide from the SUMO system has not yet been 
achieved, this work shows that the recombinant expression of C-peptide is possible 
utilizing Escherichia Coli cells. The ability to recombinantly express C-peptide is a 
low cost alternative to other methods currently available. Once a method of cleavage 
kDa 
25 
20 
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is developed, C-peptide can be expressed and we can begin utilizing it for oral 
delivery experiments using B12. 
 
7 Future Work 
7.1 C-peptide Expression and Confirmation 
Once the cells are lysed properly, a purification method to isolate the SUMO 
Xa C-peptide will be developed. Using the Factor Xa protease, we will cleave C-
peptide from the SUMO system. We will then purify the C-peptide using Factor Xa 
binding beads.  
After the recombinant expression and purification of C-peptide is achieved, we 
are going to run diagnostic tests that support its synthesis.  This will include a 
Western blot and an Enzyme-linked immune sorbent assay (ELISA), which uses 
antibody recognition to confirm C-peptide’s presence. Also, Circular Dichroism (CD) 
will be conducted to determine the folding state and MALDI-ToF will be performed 
to support the presence of C-peptide by using its mass to charge ratio. 
7.2 Oral Delivery of C-peptide 
Using the 5’-carboxylic acid B12 derivative we have made, we are going to 
conjugate C-peptide to B12. In order to make the oral delivery of C-peptide feasible, 
C-peptide cannot lose its function when conjugated to B12. C-peptide needs to be 
conjugated using its carboxyl terminus. Because a carboxylic acid and carboxylic acid 
cannot be coupled, a linker will be used. We will use ethylenediamine to link the 5’-
carboxylic acid to the carboxyl terminus of C-peptide. Although this will add two 
carbons, it should allow C-peptide to maintain its function in the body.    
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Capstone Summary 
 
Diabetes is a group of disease categorized by high levels of blood glucose 
(sugar). Insulin is a hormone produced by the body that regulates blood glucose 
levels. Therefore, diabetes can be a result of defective insulin production, use, or a 
combination of both. The two main types of diabetes are type 1 and type 2.  
Currently patients with diabetes receive most of their treatments/therapeutics, 
including insulin, subcutaneously via an injection or pump. Although oral 
administration of these therapeutics would be an ideal alternative route of delivery in 
order to increase patience compliance and comfort, two main barriers stand in the 
way. First of all, the acidic environment of the stomach and digestive system would 
degrade any protein or peptide that was ingested, leaving it unable to function 
properly in the body. Second of all, the body does not have a method or pathway to 
absorb these peptides and proteins into the bloodstream so they would just stay in the 
digestive system and would not function in the body. If these two problems could be 
solved, then the oral delivery of peptides and proteins would be a feasible method to 
deliver medications, improving the lives of many. The ability to deliver insulin orally 
would increase the ease at which it can be administered to those with diabetes. This 
could significantly increase patient compliance, lowering the complications and 
deaths each year caused by diabetes. 
Utilizing the Vitamin B12 uptake pathway is one proposed method of oral 
delivery of protein therapeutics. The utilization of the B12 uptake pathway has been a 
method of oral delivery of peptides and protein receiving increasing attention over the 
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past decade. If proteins and peptides can be linked or conjugated to B12, B12’s 
pathway and mechanism for delivery within the body naturally has ways to protect 
the proteins and peptides from the acidic environment in the gastrointestinal tract and 
allow them to be absorbed into the bloodstream. 
When coupling B12 and a peptide, protein, or any other molecule, it is 
important that both entities maintain their biological function in the body. The 
functional sites of the peptide, protein, or molecule must still be intact in order to 
work properly once it reaches the bloodstream. In addition, the site on B12 recognized 
by the proteins in its uptake pathways must still be recognizable. Therefore, vitamin 
B12 only has select positions that a protein can be conjugated to. 
Conjugation has most successfully occurred at (1) the 5’-hydroxyl group of 
the ribose and (2) the e propionamide of the peripheral corrin ring. The 5’-hydroxyl 
group of the ribose of B12 is a versatile site that could potentially be used for the 
synthesis of a variety of B12 conjugates. However, limited chemistry with a hydroxyl 
group can be performed and the conjugates synthesized using this site are done 
through a carbamate or ester bond, which present stability issues. Also, it creates 
potential for degradation or breaking of the bonds used to conjugate the two entities. 
One way to solve this problem would be to change the hydroxyl group on B12 into a 
group, such as a carboxylic acid, that allows for a greater variety of chemistry as well 
as a more stable bond. 
We investigated a way to synthesize a derivative of Vitamin B12 (B12) that 
could increase the ease of its conjugation to proteins and peptides. The 5’-position of 
the ribose tail of B12 was oxidized to a carboxylic acid using excess 2-iodoxybenzoic 
44 
 
 
acid (IBX) and 2-hydroxypyridine (HYP). The synthesis of this B12 derivative allows 
for peptides, proteins, and other molecules to be conjugated to the 5’-position of the 
ribose tail of B12 using a more stable amide bond instead of a carbamate bond.  
In conclusion, we have successfully made a form or derivative of B12 that 
could increase the ease at which B12 conjugates are made. We have shown that IBX 
can be used to specifically oxidize the 5’ site of B12. The B12 derivative synthesized 
was done with a yield that triples the synthesis of any other reported carboxylic acid 
derivative of B12. It is also much easier to purify and quicker to make. The formation 
of a derivative of B12 that has a carboxylic acid instead of a hydroxyl group available 
for conjugation increases the chemistry that can be performed at the 5’ site. This will 
allow higher yielding and more stable conjugates to be formed in the future. This 
conjugate will be of significant use in the field of B12 conjugation chemistry. 
C-peptide is a protein that is part of the proinsulin. Proinsulin is the form of 
insulin before it is activated for use as a hormone in the body. After C-peptide is 
cleaved from proinsulin, Insulin is released into the body in its active form, along 
with the same amount of C-peptide. For a long time, C-peptide was thought to be 
biologically inactive and did not have a significant role in the body.  People with 
diabetes therefore only received injections of supplemental insulin, not C-peptide. 
However, recent studies have suggested that C-peptide may serve a regulatory role in 
the body by contributing to vascular homeostasis in various tissues. For patients with 
diabetes, the lack of C-peptide in combination with high blood glucose levels reduces 
circulation, which can eventually lead to complications like neuropathy. Neuropathy 
is the disease or dysfunction of nerves. The administration of C-peptide has the 
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potential to reduce diabetic neuropathy. Diabetic neuropathy most commonly leads to 
limb amputations. Currently a subcutaneous administration of C-peptide is being 
studied for use in patients with diabetes, however the ability to deliver C-peptide 
orally has the potential to be more convenient for patients with diabetes and therefore 
increase patient compliance. Utilization of the B12 uptake pathway by conjugating C-
peptide to the 5’-carboxylic acid derivate of B12 we have created (B12 CA), could 
allow the oral delivery of C-peptide. 
We have successfully created a method to recombinantely express C-peptide 
using Escherichia coli or a type of bacteria. We have expressed C-peptide using a 
SUMO system. The SUMO system is added in order to purify C-peptide and extract it 
for use. The problem we are currently facing is cleaving or cutting C-peptide from the 
SUMO system. Currently we are investigating alternative methods to solve this 
problem. After this is completed, the next step will be conjugating C-peptide to B12 
for oral delivery studies. 
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Abstract: Reaction of vitamin B12 (B12) with excess 2-iodoxyben-
zoic acid and 2-hydroxypyridine leads to selective oxidation of the
5 -hydroxyl group of the ribose tail of B12 in a 30% isolated yield.
The acid derivative was purified in one step by HPLC chroma-
tography and characterized by MALDI-TOF mass spectrometry,
1H NMR and 2D (HSQC and HMBC) NMR. The new carboxylic
acid derivative is perfectly suited to make stable amide-based B12
bioconjugates. 
Key words: vitamins, oxidation, 2-iodoxybenzoic acid, carboxylic
acids, cobalamin
Interest in using vitamin B12 (B12) for the oral delivery of
peptides and proteins1 has encouraged us to further ex-
plore the available conjugate sites of B12. Modifications of
B12 that allow for more facile, higher yielding or stable
bioconjugate formation with continued recognition by B12
dietary uptake and transport proteins have been explored
by numerous groups.2–4 Several functional groups are
available on B12 for conjugation, including the 5 -hydrox-
yl group of the ribose tail, the cobalt(III) ion, the phos-
phate moiety, and suitably modified propionamides off
the corrin ring.5 All such modifications suffer from issues
including reduced or complete loss of interaction with one
or more of the B12 binding proteins, stability issues that re-
sult from the production of ester or carbamate bonds, low
yielding conjugation reaction due to the nature of the
functional group, or require problematic purification of
the modified B12 for subsequent conjugation.2–4 These
limitations have been well investigated6 and a review of
such sites has been reported,7 however, in brief for pur-
poses of perspective for the work described herein: Con-
jugation resulting in the recognition of all three transport
proteins has been most successful with B12 at two major
sites: (i) the peripheral corrin ring e-propionamide, and
(ii) the 5 -hydroxyl group of the ribose unit of the a-‘tail’.
The side chain e-carboxylic acid derivative (Figure 1) al-
lows for a variety of modifications,8 but the synthesis of
the derivative is low yielding and requires laborious puri-
fication, the result, in part, of the formation of b- and d-
carboxylic acid isomers in addition to the desired e-iso-
mer.9 The 5 -hydroxyl group has been cited as being a
more versatile site according to structure–activity rela-
tionships, however, the conjugates have typically been
synthesized as mentioned above, through carbamate or es-
ter bonds. 
Figure 1  Potential sites available for carboxylic acid formation that
also maintain, at least in part, B12 uptake protein recognition and bind-
ing are indicated in red. The atom numbering scheme used for NMR
discussion is also indicated 
The goal of this work was to create a simple route for the
production of a 5 -carboxylic acid derivative of B12 with
facile purification to ultimately produce stable amide-
linked bioconjugates at this optimal position for conjuga-
tion, especially in regard to intrinsic factor binding (criti-
cal for oral uptake of B12 bioconjugates).10 Herein, we
report the use of the hypervalent iodine reagent, 2-iodoxy-
benzoic acid (IBX) for the selective oxidation of the
5 -hydroxyl group of B12 to the corresponding carboxylic
acid. This is the first time IBX has been utilized for the ox-
idation of such a molecule as B12 and expands the range of
use of this environmentally friendly oxidizing agent.11 
The B12 derivative was synthesized through a modifica-
tion of the method developed by Giannis et al., which in-
corporates the addition of an O-nucleophile to aid IBX in
the transformation of a primary alcohol into a carboxylic
acid (Scheme 1).12 The use of N-hydroxysuccinimide
(NHS) was initially attempted but resulted in the forma-
tion of a product mixture from which it was not possible
to isolate the carboxylic acid, likely due to the formation
of the activated NHS ester, which has been reported as a
dominating product of this reaction.12 Therefore, 2-hydroxy-
pyridine (HYP) was used as the O-nucleophile. To opti-
mize the reaction conditions, a series of experiments were
performed in which the co-oxidant, temperature, and time
were varied (Table 1). The best result was obtained in the
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presence of 2.6 equivalents of IBX and 5 equivalents of
HYP in dimethyl sulfoxide (DMSO) at 60 °C.
Scheme 1  Purposed mechanism for the formation of the 5 -carbox-
ylic derivative utilizing IBX and HYP
These conditions resulted in the oxidation of B12 to the
5 -carboxylic acid derivative B12CA in two hours with a
30% yield (see the Supporting Information). It was deter-
mined that a 30% yield was optimal for the IBX reaction
in this case. An increase in temperature, IBX/HYP ratios,
or time resulted in an increase in the amount of byproducts
and/or decomposition of the B12 (especially at tempera-
tures in excess of 60 °C), reducing the yield and compli-
cating purification. The 30% yield is approximately three
times that previously reported for the preparation of the e-
carboxylic acid derivative, with far easier separation (see
below).9 
The crude reaction mixture was precipitated from DMSO
by ether addition and the precipitate was redissolved in
water prior to purification by ion exchange chromato-
graphy using a SAX column. After a 5 minute hold at
100% water, a gradient from 100% water to 35% MeCN–
phosphate buffer (pH 2; 50:50 v/v) over 5 minutes was
necessary for the separation and elution of B12CA (Figure
2). Slight increases in pH above pH 2 resulted in a reduc-
tion in the amount of pure isolated product. HPLC purifi-
cation allowed the recovery and reuse of B12 starting
material, albeit with the oxidized 5 -aldehyde also present
(Figure 2). B12CA was identified as the peak at 13.6 min-
utes retention time. The purity of B12CA was at least 95%,
as assayed by RP-HPLC. MALDI-TOF mass spectrome-
try analysis of B12CA revealed the anticipated molecular
ion peak (m/z = 1343.5 [M – CN]+; Figure 3). 
Figure 2  The RP-HPLC spectra of 5 -carboxylic acid
(tR = 13.6 min) monitored at 360 nm. Unreacted B12 and 5 -aldehyde
co-elute at tR = ca. 5 min, as indicated by MALDI-TOF MS (see also
Figure S1 in the Supporting Information)
Electronic absorption spectroscopy (EAS) was used to es-
tablish the oxidation state of the metal center as Co(III),
with no indication of derivation of the axial ligands bound
to the metal center ( CA361 = 27500 M–1cm–1; see Figure 4)
The structure of B12CA was determined on the basis of 1H
NMR (see Figure S2) and 1H–13C heteronuclear (HSQC
and HMBC) correlations (see Figures S3 and S4). The 1H
NMR spectra of B12CA revealed the loss of two protons
( H = 3.75 and 3.92 ppm), when compared to the spectrum
of B12 (CNCbl; see Figures S2 and S5). A comparison of
the HSQC of B12 and B12CA indicates the protons that are
absent in B12CA were originally attached to the R5 carbon
( C = 63.5 ppm; see Figure S6). HMBC was attempted to
further establish the presence of a carbonyl at the R5 po-
sition (see Figure S4), however, it was not possible to as-
sign the R5 carbon from the HMBC spectra because it
Table 1  Optimization of the Reaction Conditions
Entry Co-oxidant Temp (°C) Time (h) Yield (%)
1 None 50 2 17
2 HYP 50 2 23
3 HYP 50 3 26
4 HYP 50 4 28
5 HYP 50 5 22
6 HYP 60 2 30
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showed no connectivities to any of the ribose protons, and
so was assigned by HSQC.13
A simple amine-containing organic molecule, benzyl-
amine, was conjugated to the derivative to help with the
identification of the R5 carbon by NMR analysis. In the
presence of 10 equivalents of ethyl-3-(3-dimethylaminopro-
pyl)-carbodiimide (EDC) and 20 equivalents 1-hydroxy-
benzotriazole (HOBt) in N,N-dimethylformamide (DMF)
with 1% water, the desired conjugate was produced at
40% yield over the first hour (Scheme 2), thus establish-
ing proof-of-concept for the new B12CA.
The conjugate was purified by using the same purification
method established for the carboxylic acid (Figure 5) and
characterized by MALDI mass spectrometry (Figure S7)
as well as 1D (Figure S8) and 2D NMR (Figures S9 and
S10) spectroscopy.
With the addition of the benzylamine, connectivity to the
R5 carbon was established by HMBC (Figure 6). Specifi-
cally, the protons of CA ( H = 4.42 and 4.50 ppm) showed
direct connectivity to the R5 carbon ( C = 173.8 ppm) as
well as to CB ( C = 140.8 ppm) and CC ( C = 131.4 ppm)
of the benzylamine. The complete assignment of B12CA
and B12CABA can be found in Table S1. 
In conclusion, we have developed a convenient site-spe-
cific oxidation of B12 using IBX and HYP. This new car-
boxylic acid derivative is highly suited to the production
Figure 3 MALDI-TOF MS spectrum of HPLC peak at tR = 13.6 min,
indicating B12CA (m/z = 1343.5 [M – CN]+) with angiotensin I (m/z =
1296.5) as an internal reference 
Figure 4 Absorbance spectrum of 5 -carboxylic acid derivative in
35% HPLC mobile phase B 
Scheme 2 Synthesis of 5 -carboxylic acid plus benzylamine
Figure 5 Purification of the conjugate was established by RP-HPLC
using an SAX column with a gradient from 100% water to 35%
MeCN–phosphate buffer pH 2
Figure 6Analysis of the B12 5 -carboxylic acid benzylamine deriva-
tive by 2D heteronuclear NMR spectroscopy. (A) The atom number-
ing scheme for the benzylamine attached to R5 of B12 by an amide
bond. (B) Signal assignments made from HSQC. (C) Signal assign-
ments made from HMBC (both 1H and 13C assignment for CA were
made on the basis of HSQC analysis)
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of bioavailable amide bound bioconjugates. The one-step
purification is simple and the synthesis results in a 30%
yield within two hours, which is far in excess of any pre-
viously reported B12 carboxylic acid derivative.9 The re-
sulting derivative has the potential to form high-yielding
conjugates and we believe will be of considerable use in
the field of B12 conjugation. 
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